Hyperhidrosis most commonly affects the armpits, followed by the palms of the hands and the soles of the feet. Impairment of quality of life differs based on where primary hyperhidrosis manifests on ...

Hyperhidrosis is undertreated and underappreciated as a condition that causes distress for patients, yet available treatment ...

Please provide your email address to receive an email when new articles are posted on . Candesant Biomedical announced positive results from its pilot study on the targeted alkali thermolysis patch, ...

The FDA approved sofpironium topical gel 12.45% (Sofdra) for primary axillary hyperhidrosis, according to a statement from Botanix Pharmaceuticals. The approval stipulates use in adults and children 9 ...

The US Food and Drug Administration (FDA) today cleared the first patch to reduce excessive underarm sweating for adults with primary axillary hyperhidrosis. The single-use, disposable, ...

Sofpironium bromide is a structural analogue of glycopyrrolate, an anticholinergic agent. Positive topline results were announced from 2 identical phase 3 studies evaluating sofpironium bromide in ...

The Food and Drug Administration has approved a topical anticholinergic, sofpironium topical gel, 12.45%, for the treatment of primary axillary hyperhidrosis in adults and children aged ≥ 9 years.

Sofdra (sofpirnium) is a new topical gel for hyperhidrosis, a common disorder that can lead to gushes of perspiration no matter the weather. In clinical trials, Sofdra (sofpironium), a topical gel, ...

Sofpironium bromide in the treatment of primary axillary hyperhidrosis improves Hyperhidrosis Disease Severity Scale scores, reduces gravimetric weight of sweat, and improves Dermatology Life Quality ...

Sofpironium bromide indirectly reduces the rate of sweating by preventing the stimulation of acetylcholine receptors that are located on sweat glands. The Food and Drug Administration (FDA) has ...

There is not much good evidence about how well this procedure works or how safe it is for severe primary axillary hyperhidrosis. This procedure can be used but only when patients are having regular ...

MENLO PARK, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering ...